Press "Enter" to skip to content

‘That Is in the Shocking Category’: What We Heard This Week

“I don’t think any of us would have expected a 60% pathologic complete response rate 10 weeks after SABR — and that’s just not surprising, that is in the shocking or startling category.” — Dennis Wigle, MD, PhD, of the Mayo Clinic in Rochester, Minnesota, on a study of stereotactic ablative radiotherapy (SABR) in early, operable lung cancer that underwhelmed.

“Her labor curve was phenomenal.” — Patricia Rekawek, MD, of Icahn School of Medicine at Mount Sinai in New York City, who presented data at the Society of Maternal-Fetal Medicine meeting for a colleague who left the meeting early when his wife went into labor.

“Fifty percent is not good enough when you’re talking agents that can kill people almost instantly.” — Raeford Brown Jr., MD, chair of the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee, after reviewing an FDA report and other documents showing that as many as half of the patients taking transmucosal immediate-release fentanyl drugs should not have had a prescription.

“We found that the majority of states are losing more life-expectancy years to opioids than to guns or car accidents.” — Mathew Kiang, ScD, commenting on a study that identified “hot spots” in the U.S. opioid epidemic.

“As a black woman, it gets really depressing to hear the bad news and not to hear any interventions.” — Laura Riley, MD, of Weill Cornell Medical Center in New York City, on study results showing that a texting-based intervention for blood pressure monitoring virtually eliminated racial disparities in postpartum care as compared with office visits.

“This may change practice habits because we could opt not to prescribe narcotics post-discharge, or if we do, we could give patients fewer tablets.” — Angela Bianco, MD, of the Icahn School of Medicine at Mount Sinai, commenting on study showing that non-opioid analgesia following cesarean delivery led to a lower mean pain score as compared with opioid-containing patient relief.

“How do we provide the right balance between risk and benefit of certain ventilation strategies in these patients with ARDS?” — Jeremy Beitler, MD, MPH, of the University of California, San Diego, on study results showing that mechanical ventilation with esophageal pressure-guided positive end-expiratory pressure did not improve the primary outcome in patients with moderate-to-severe acute respiratory distress syndrome (ARDS).

2019-02-22T18:00:00-0500

Source: MedicalNewsToday.com